PARADIGM-HF
A multicenter, randomized, double-blind, parallel group active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction.
The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II – IV and EF< 40%).
Principal Investigator: Nathan Laufer, MD
Sponsor: Novartis
Enrollment Status: Open